Head-to-head evidence
CTX310 vs Evinacumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: ANGPTL3 · full Atherosclerotic Cardiovascular Disease pipeline
CTX310
Developed by CRISPR Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07491172 (registry estimate)
Evinacumab · Evkeeza
Marketed by Regeneron Pharmaceuticals
NCT03399786 · Phase 3 · completed
The trial randomized 65 participants to evinacumab or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary LDL-C endpoint was statistically significantly improved with evinacumab, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical or endoscopic measure.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CTX310's landscape · Evinacumab's landscape